
Oncology NEWS International
- Oncology NEWS International Vol 16 No 4
- Volume 16
- Issue 4
Eisai to Acquire Morphotek to Expand into Biologic Therapeutics
Eisai to Acquire Morphotek to Expand into Biologic Therapeutics
TOKYO, JapanEisai Co. Ltd and Eisai Corporation of North American (Woodcliff Lake, New Jersey) have signed a definitive agreement to acquire Morphotek (Exton, Pennsylvania) for $325 million. The acquisition is pending subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act. Morphotek develops therapeutic monoclonal antibodies and is evaluating two in early-stage clinical trials. Eisai's portfolio of oncology drugs currently includes small-molecule anticancer agents.
Articles in this issue
about 19 years ago
Curcumin Evaluated for the Treatment of Pancreatic Cancerabout 19 years ago
Tykerb Approved for Metastatic HER2+ Breast Cancerabout 19 years ago
Drug for BPH May Also Reduce the Risk of Prostate Cancerabout 19 years ago
Phase III Trial of Prostvac-VF Is Launchedabout 19 years ago
Electronic System Reminds Patients to Schedule Examsabout 19 years ago
Phase II Trial of Panzem for Renal Cell Carcinoma Initiatedabout 19 years ago
Chemotherapy May Enrich Tumorigenic Cells in Breast Caabout 19 years ago
Watchful Waiting Management for Prostate Ca a Hard SellNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Related Content





















































